Millions of cancer survivors experience a persistent neurological syndrome that includes
deficits in memory, attention, information processing, and mental health. Cancer therapy …

Cancer-related cognitive impairment (CRCI) is commonly experienced by individuals with
non-central nervous system cancers throughout the disease and treatment trajectory. CRCI …

Brain-derived neurotrophic factor (BDNF) improves cognitive function by stimulating
neurogenesis and neuroplasticity. We hypothesize that higher plasma BDNF levels are …

Traditional cancer therapies induce lasting alterations to multiple neural cell types. Therapy-
induced microglial activation is a critical component of the cause of CRCI, contributing to …

Brain-derived neurotrophic factor (BDNF) plays an essential role in neurogenesis and
neuroplasticity and may be a key protein in cancer-related cognitive impairment (CRCI). This …

A decline in cognitive function following cancer treatment is one of the most commonly
reported post-treatment symptoms among patients with cancer and those in remission, and …

Purpose Brain-derived neurotrophic factor (BDNF) and the BDNF Val66Met polymorphism
(rs6265) have been implicated in neurodegenerative conditions. This study aimed to …

Objective Cancer‐related cognitive impairment (CRCI) among adolescent and young adult
(AYA) cancer patients with noncentral nervous system (CNS) cancers has not been well …

Alzheimer's disease (AD) is the most common type of dementia and one of the leading
causes of death in elderly patients. The number of patients with AD in the United States is …

Patients with cancer may suffer from a decline in their cognitive function after various cancer
therapies, including surgery, radiation, and chemotherapy, and in some cases, this decline …